| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,156,071 ) |
| | 2025 | 2025 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 000 | 3 | NIH | 12/6/2024 | $1,209,751 |
| | 2025 | 2025 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 001 | 3 | NIH | 3/13/2025 | $50,000 |
| | 2025 | 2022 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 000 | 1 | NIH | 1/22/2025 | -$103,680 |
|
| Issue Date FY: 2024 ( Subtotal = $1,248,699 ) |
| | 2024 | 2024 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 001 | 2 | NIH | 12/8/2023 | $1,248,699 |
| | 2024 | 2024 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 003 | 2 | NIH | 7/8/2024 | $158,532 |
| | 2024 | 2022 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 3 | NIH | 3/18/2024 | $0 |
| | 2024 | 2022 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 001 | 3 | NIH | 7/17/2024 | $0 |
| | 2024 | 2022 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 000 | 1 | NIH | 8/14/2024 | $0 |
| | 2024 | 2021 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 000 | 1 | NIH | 12/7/2023 | $0 |
| | 2024 | 2021 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 002 | 1 | NIH | 7/8/2024 | -$158,532 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 000 | 1 | NIH | 10/24/2022 | $0 |
| | 2023 | 2022 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 001 | 1 | NIH | 2/28/2023 | $0 |
| | 2023 | 2022 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 002 | 1 | NIH | 7/10/2023 | $0 |
| | 2023 | 2021 | IMMUNOCHEM THERAPEUTICS LLC | 105 AUBURN ST | AUBURNDALE | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 000 | 1 | NIH | 7/18/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,220,435 ) |
| | 2022 | 2022 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 002 | 3 | NIH | 7/28/2022 | $722,072 |
| | 2022 | 2022 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44NS124443 | Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH) | 000 | 1 | NIH | 9/18/2022 | $498,363 |
| | 2022 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 001 | 2 | NIH | 7/22/2022 | $0 |
| | 2022 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 2 | NIH | 11/9/2021 | $0 |
| | 2022 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 000 | 2 | NIH | 10/18/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,227,416 ) |
| | 2021 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 2 | NIH | 8/20/2021 | $777,049 |
| | 2021 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 001 | 2 | NIH | 9/9/2021 | $777,049 |
| | 2021 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 001 | 2 | NIH | 9/9/2021 | -$777,049 |
| | 2021 | 2021 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG071062 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk | 000 | 1 | NIH | 8/31/2021 | $450,367 |
| | 2021 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 000 | 2 | NIH | 8/2/2021 | $0 |
| | 2021 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R42CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 1 | NIH | 7/29/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R42CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 1 | NIH | 3/2/2020 | $0 |
| | 2020 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 000 | 2 | NIH | 5/18/2020 | $0 |
| | 2020 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 003 | 2 | NIH | 9/22/2020 | $0 |
| | 2020 | 2018 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 001 | 1 | NIH | 6/12/2020 | $0 |
| | 2020 | 2018 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 002 | 1 | NIH | 9/13/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,382,741 ) |
| | 2019 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 001 | 2 | NIH | 9/14/2019 | $1,157,853 |
| | 2019 | 2019 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R42CA236382 | Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction | 000 | 1 | NIH | 4/30/2019 | $224,888 |
| | 2019 | 2018 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 000 | 1 | NIH | 9/13/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $499,320 ) |
| | 2018 | 2018 | IMMUNOCHEM THERAPEUTICS, LLC | 105 AUBURN ST | NEWTON | MA | 02466-2524 | MIDDLESEX | USA | R44AG060846 | First-in-human study of MW151, a novel drug targeting neuroinflammation | 000 | 1 | NIH | 9/18/2018 | $499,320 |
|
|
